Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

River blindness vaccine set for cattle trials
The vaccine is being developed by biotechnology company Vaxine Pty.

Vaccine uses unique sugar-based adjuvant

Scientists in Australia are developing a vaccine that could prevent millions of cases of river blindness.

According to The Lead South Australia, the vaccine is being developed by biotechnology company Vaxine Pty and is set for trials in 2017.

Vaxine scientific director Nikolai Petrovsky explained that the vaccine uses a two-pronged approach to effectively prevent the disease.


“First we’re looking to vaccinate the cattle, which are a breeding ground for the parasite,” he said. 
“Then, the other side of this is to immunise the children so if they come in contact with the parasite it blocks the infection.


“Our technology is a bit like melding a turbocharger to the engine and in this case makes the vaccine dramatically more powerful.”

According to the World Health Organisation, river blindness affects some 17 million people globally. Ninety per cent of these cases occur in west and central Africa.


Caused by the parasitic worm Onchocerca volvulus, river blindness is spread to humans and cattle by blackflies that breed in rivers. Symptoms of the disease include severe itching, disfigurative skin conditions and visual impairment - including permanent blindness.

Professor Petrovsky said the new vaccine uses a unique sugar-based adjuvant, which is safer than existing methods.

“We offer a new alternative that is not only potentially safer because it is a sugar instead of a metal/salt with high toxicity,” he told The Lead. 

“Our adjuvant also works for a lot of vaccines that wouldn’t work with aluminium. The ones that tried to create an onchocerciasis vaccine didn’t take but ours actually works.”

The vaccine was developed in association with Thomas Jefferson University and the New York Blood Centre in the United States.

The team have received a grant from the US government and hope to begin tests for the cattle trial in the coming weeks.

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.